About the Report
The rising prevalence of respiratory disorders has necessitated innovation in manufacture of respiratory inhalers. The demand for better precision in drug delivery is enabling broader adoption of respiratory inhaler devices, especially among patients of asthma and chronic obstructive pulmonary diseases (COPD). Steady growth is expected to continue as favorable reimbursement policies by governments create a conducive environment around the world.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for respiratory inhalers. The report tracks the global sales of respiratory inhalers in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on the medical device industry in general, and respiratory inhaler devices in particular.
Historical and Future Outlook
Chronic obstructive pulmonary diseases (COPD) represent a major health concern and have been reported by the World Health Organization (WHO) as one of the leading causes of death. Pharmaceutical drugs and effective medical devices have remained key to management of COPD and other respiratory diseases.
For instance, Sustainable Development Goals (SDG) created by the United Nations in 2016 were intended at improving living standard globally. Likewise, the Forum of International Respiratory Societies (FIRS) was a part of a worldwide call for action to address the soaring burdens of respiratory diseases. These efforts have been crucial in driving demand for respiratory inhalers. According to FMI’s analysis, respiratory inhaler sales have grown at 3.4% CAGR between 2015 and 2019.
A slew of new drugs were launched for the management of asthma and COPD over the last decade and development of more are currently underway. With leading drug manufacturers expecting the demand to surge amid COVID-19, respiratory inhaler sales are set to grow steadily through 2030.
The pandemic crisis has resulted in the fast-tracking of drug approval, a trend most welcome by drug manufacturers. In a statement the U.S. Food and Drug Administration (USFDA) has recognized the surging demand for albuterol products amid pandemic crisis. The organization also reiterated its commitment to facilitating access to medical products in the statement. These developments present a positive outlook for growth. FMI expects global respiratory inhalers market to grow at 4.4% CAGR through 2030.
Will Combination Therapies Influence Respiratory Inhaler Demand?
The adoption of combination therapies for treatment of COPD and asthma has grown steadily. The rising adoption of combination therapies such as triple combination therapy is a favorable factor for respiratory inhaler manufacturers.
Precision in drug delivery is imperative for these therapies to be effective and inhaler devices are considered as the most efficient medium enabling accurate dosage of drugs. Combination therapies are considered reliable source of treatment for complex patients. Besides this, favorable reimbursement policies have been encouraging adoption of these therapies.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
What is the Commercial Potential of Smart Inhaler Technology?
A report, titled “Smart Asthma” published in 2017, Asthma U.K. highlighted concerns pertaining to the need for health systems to plan well in advance so that full potential of smart inhaler technology can be realized. With several companies prioritizing the launch of smart inhaler devices, growth opportunities seem impressive. Positive results from studies conducted on smart inhaler devices and applications trials have piqued the interest of some of the leading pharmaceutical companies.
Boehringer Ingelheim, Novartis, and GlaxoSmithKline have signed development deals with Propeller Health, while AstraZeneca has entered into a master supply agreement with Adherium.
Why R&D is Key to Market Consolidation?
Some of the leading companies are investing in research and development to gain competitive advantage. For instance, CIPLA is currently investigating across resources in the U.S. to expand its franchise. Besides this, it already has completed the phase 3 trial of g-Advair and is waiting to subsequently file for USFDA approval. With companies around the world increasingly focusing on research initiatives, expansion is on card.
Inhaler medication continues to remain a cornerstone for administering treatment to patients with respiratory disorders. The benefits of respiratory inhalation therapies have long been identified. With the demand for more efficient delivery systems rising, the focus on research and development will increase.
What is the Regulatory Impact on Global Sales?
The World Health Organization has forecast COPD to become the third leading cause of death around the world by 2025. The rising incidence of respiratory ailments and the increasing demand for effective treatment has been creating lucrative opportunities for growth. With the implementation of conducive reimbursement policies, the market is expected to gain significant impetus in the coming years.
Improvements in standard healthcare policies and rising focus towards making advanced treatment better accessible will create lucrative growth prospects. For instance, the implementation of the Affordable Care Act helped nearly forty million uninsured Americans gain access to healthcare services.
Likewise, health services are largely free in England. The National Health Service (NHS) provides primary care, preventive medicines, and hospital services to “ordinarily resident” in the country. From 2018, radical changes were introduced in NHS that will allow social care leaders to formally devise care for individual patients, which will be increasingly made available away from hospitals. These developments aimed at making healthcare better accessible will present a conducive environment for respiratory inhalers sales.
Similarly, Japan’s universal healthcare system is known for keeping its population healthy at an exceptionally low cost. According to OCED, Japan’s healthcare reform focuses on controlling costs, while improving the quality of care. Presence of favorable regulatory environment will continue bolstering sales prospects through the forecast period.
How Big is the Opportunity in US?
FMI has projected North America to remain one of the most lucrative markets throughout the course of the forecast period. One of the key factors supporting expansion is the region’s high healthcare spending. According to preliminary forecasts by CMS’ Office of the Actuary, the overall healthcare spending in the United States alone is likely to increase at 5.4% between 2019 and 2028, outpacing the country’s GDP by 4.3%.
Furthermore, the U.S. remains one of the largest markets for medical devices in the world, which invariably makes it a lucrative pocket for respiratory inhaler devices manufacturers. According to SelectUSA the medical devices market in the U.S. accounted for 40% of the global market in 2017. By 2023, it is expected to reach US$203 billion. As per the Centers for Medicare & Medicaid Services (CMS), retail spending for durable medical equipment in the U.S. stood at US$54.4 billion in 2017. It is projected to increase in the coming years, which is indicative of remarkable scope for expansion it will offer to respiratory inhaler devices companies.
Favorable healthcare policies, coupled with high per capita healthcare spending, has created a conducive environment for the adoption of respiratory inhaler devices in the U.S. Also the presence of leading players such as Merck & Co. is supporting growth in the U.S. Strategies undertaken by these companies include product launches and expansion plans, which will continue aiding overall expansion in the U.S.
UK’s Medical Device Sales Need Revival
The adoption of respiratory inhalers devices is expected to rise considerably across hospitals and healthcare facilities in countries across UK. As a result of efforts by various government organizations such as the European Academy of Allergy & Clinical Immunology to spread awareness about COPD and asthma, the demand for respiratory inhaler devices is expected to surge. Europe is identified by FMI as the second-leading market, a position it is likely to hold on to through the forecast period.
According to a research by the University of Edinburgh COPD care costs in England is likely to exceed £2.5bn by 2030. This is indicative of rising health expenditure on treatment of respiratory ailments, which represents scope for the expansion in the U.K. According to the Organization for Economic Co-operation and Development, U.K. spent nearly £2,989 per person on healthcare in 2017. With healthcare spending in the U.K. forecast to surge significantly, sales prospects are likely to get better.
Why Innovation is Key to Succeed in German Medical Device Market?
The Federal Statistical Office has reported that healthcare spending in Germany rose by 4% in 2018 from 2017. In 2018, the country’s healthcare spending accounted for 11.7% of the GDP. Furthermore, health expenditure was expected to surge to 407.4 billion Euros by 2019, presenting a lucrative landscape for the expansion of the respiratory inhaler devices.
Also presence of companies such as Boehringer Ingelheim GmbH is supporting the expansion in Germany. The company has launched Respimat® inhaler in Germany in April 2020. Besides this, the company has been investing significantly in expansion efforts. Growth strategies adopted by these companies are expected to aid the expansion in Germany.
Since 2009, health insurance has been made mandatory for all citizens of the country. According to NCBI, a total of 70 million people, which roughly covers 85% of the population are covered by statutory health insurance. Another 11% population of Germany is covered by substitutive private health insurance. Conducive reimbursement policies and regulatory scenario are presenting attractive opportunities for growth.
Sales in France Tied Closely to Healthcare Spending
According to the National Center for Biotechnology Information (NCBI), French survey results showed that COPD patients required considerable use of healthcare resources, with annual direct cost incurred, estimated to be at Euro 530 per patient. Additionally, another survey by NCBI revealed that prevalence of severe asthma was estimated to be around 0.18% to 0.51% among French adults. The high burden of respiratory disease in France is leading to increasing demand for effective treatment measures. The demand for respiratory inhaler devices is therefore expected to remain considerably high in the country.
Healthcare spending in France stood nearly at 11.25% of the GDP in 2018 as per the World Bank. While this represented a slight decline than healthcare spending of previous year, the position of healthcare continues to remain that of national responsibility in the country. Coupled with favorable government policies, a surging incidence of respiratory illnesses will keep the demand for respiratory inhaler devices high in France.
Growing COPD Prevalence in China to Create a Surge
While US and Europe will continue leading, growth in South Asia is expected to happen at an accelerated pace. According to the World Health Organization, 3 million people around the world died of COPD in 2012 and 90% of COPD deaths were recorded in low and middle income countries, including China.
A nationwide survey conducted in China revealed that prevalence of COPD among people aged 40 years and above was 8.2% in 2008. Based on results revealed in the Global Burden of Disease Study, COPD was third-leading cause of death in the country in 2010. These figures are indicative of opportunities for wider penetration in China, subsequently South Asia.
What’s the Market Share of Dry Inhalers?
The dry powder inhaler (DPI) segment will continue accounting for over half of the global share among products through the forecast period. According to FMI, the segment is expected to hold a little below 54% of the market, in terms of product type, by the end of 2030. Dry powder inhalers offer greater precision and straightforward usage, which are the leading causes behind dominance of the segment.
Convenient mechanism of DPIs is enabling their uptake for drug delivery in COPD and asthma treatment. However, in the coming years an increasing number of patients are likely to switch to metered dose inhalers on grounds of improved disease control and reduced exacerbations.
Why Manual Inhaler Devices Hold 90% Share?
Accounting for over 90% of the overall share through the forecast period, manually operated inhaler devices continue to account for bulk of demand. Growth in the digitally operated inhaler devices segment is likely to , primarily because the technology is still at a nascent stage and is yet to become widespread.
The primary aim of manually operated inhaler devices is to optimize drug delivery to offer improved management of respiratory illnesses. The technology offers several advantages such as rapid onset of action, possibility of using precise doses of medication, and systematic absorption.
While experiments with digital inhalers are underway, manual inhalers remain widely sought-after. Experts are looking for ways to ensure that the technology adheres to correct disease management guidelines and eliminates the chances of miscalculations. Digital technologies have impressive growth prospects on card however lack of awareness could be withholding expansion of the segment to an extent.
Opportunities Abound in Asthma Treatment
According to FMI, the demand for respiratory inhaler devices will be higher for treatment of asthma. While the disease indication will continue leading, the COPD segment is expected to grow at an accelerated pace in the coming years. Besides this rising incidence of COPD, willingness surging healthcare expenditure around the world will aid the expansion of the segment.
According to the WHO, the Global Burden of Disease Study reported the prevalence of 251 million cases of COPD around the world in 2016. With the incidence of the disease forecast to rise, the demand from COPD segment is expected to surge at a higher pace in the coming years.
Companies operating in the respiratory inhaler devices market are aiming at strategic collaborations with software and digital service providers to address the requirements of an expanding patient pool. For instance, Novartis has collaborated with leading U.S. mobile technology company Qualcomm to develop an integrated smart inhaler.
There is ample focus on innovations and USFDA approval among players. Besides aiming at competitive advantage, leading players are focusing on expanding their global footprint as they await approvals from international organizations. For instance, CIPLA’s Albuterol Sulfate MDI (g-Proventil) is its first device –based inhalation product to be approved by USFDA for sales across the U.S. In addition to this, the company has successfully completed Phase-3 clinical study of g-Advair, which is poised to help CIPLA expand its portfolio across the U.S.
Some of the players are focusing to carve a niche for specific demography. For instance, OMRON has launched WheezeScan device to aid treatment of asthma among children. This launch marks the company’s effort towards achieving its “Going For Zero” mission, under which it has pledged to work towards a world sans strokes or heart attacks.
Meanwhile, Lupin has launched a Bluetooth enabled-device with a built-in sensors to track the daily metered-dose inhaler usage and consumption pattern in patients. Through these developments, companies are aiming at competitive advantage. A slew of new launches are likely in the coming years.
Some of the leading companies operating in the market are:
- Beximco Pharmaceuticals Ltd.
- Boehringer Ingelheim GmbH
- Cipla Ltd.
- GlaxoSmithKline plc.
- Koninklijke Philips N.V.
- Merck & Co., Inc.
- OMRON Healthcare Europe B.V.
- PARI Medical Holding
- Teva Pharmaceutical Industries Ltd.
*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.
Scope of the Report
Historical Data Available for
USD Million for value and Units for Volume
Key Regions Covered
North America, Latin America, Europe, East Asia, South Asia, Oceania Middle East & Africa
Key Countries Covered
US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Vietnam, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, South Africa
Key Segments Covered
Product Type, Modality, Disease Indication, and Region
Key Companies Profiled
Market Forecast, brand share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing
Key Questions Answered in the Report
- Which is the most lucrative market for respiratory inhaler devices?
US currently leads the global market for respiratory inhaler devices. Sales in US will be over 40% of total demand throughout the forecast period.
- Which is the top-selling respiratory inhaler device?
Dry powder inhalers are highly sought-after in every market. The demand for dry powder inhalers is expected to remain high in the near future, especially due to ease of usage and precision in drug delivery.
- Which technology are respiratory inhaler device manufacturers using?
Manually operated inhaler devices continue to remain the leading choice among patients with respiratory ailments. While the availability of digitally operated devices is increasing, sales is likely to accelerate at a slower pace in comparison to the former.
- Which are some of the leading companies offering respiratory inhaler devices?
Some of the leading companies offering respiratory inhaler devices are AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., among others.
- Which disease indication accounts is driving sales of respiratory inhaler devices?
The World Health Organization has identified asthma as one of the major non-communicable diseases around the world. It also estimated that more than 339 million people had asthma globally in 2016. The rising incidence of asthma around the world is fuelling the demand for respiratory inhaler devices.
Enquiry before Buying
- Is this research conducted by Future Market Insights?
Yes, the research has been conducted by expert analysts of Future Market Insights through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to research analyst.
- What research methodology is followed by FMI?
FMI follows a methodology that encompasses demand side assessment of the market, and triangulates the same through supply side analysis. This methodology is based on use of standard market structure, methods and definitions. Request detailed methodology.
- Who are the respondents for primary research?
FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. For a full list of primary respondents, please reach out to us.
- What are the sources of secondary research?
FMI conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
- Is a sample of this report available for evaluation?
Yes, you can request a sample and it will be sent to you through an email.
- How can I buy this report?
FMI provides a secure online payment system to buy report seamlessly. You can buy the report securely and safely.
- Dry Powder Inhalers
- Metered Dose Inhalers
- Compressed Air Nebulizers
- Ultrasonic Nebulizers
- Mesh Nebulizers
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
- Chronic Obstructive Pulmonary Disease
- Pulmonary Arterial Hypertension
- North America
- Latin America
- East Asia
- South Asia
- Middle East and Africa (MEA)